Twin Peaks Wealth Advisors, LLC Fate Therapeutics Inc Transaction History
Twin Peaks Wealth Advisors, LLC
- $309 Billion
- Q2 2025
A detailed history of Twin Peaks Wealth Advisors, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Twin Peaks Wealth Advisors, LLC holds 200 shares of FATE stock, worth $282. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200Holding current value
$282% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding FATE
# of Institutions
150Shares Held
83.4MCall Options Held
179KPut Options Held
13.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$18.2 Million1.75% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$14.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$12.4 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$6.41 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.4MShares$4.79 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $137M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...